Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (IoT) technology businesses, has announced a number of changes to the Company’s Board of Directors. Tern is pleased to announce the appointment of Jane Karwoski (known as “Jane McCracken”) and Iain Ross as independent Non-Executive Directors of the Company with immediate effect. Sarah Payne and Alan Howarth have stepped down from the Board with immediate effect to concentrate on their other business interests.
Following these changes the Board now comprises Ian Ritchie (Non-Executive Chairman), Jane McCracken (Non-Executive Director) and Iain Ross (Non-Executive Director).
Jane McCracken has spent her career working with high growth technology businesses based in the USA. UK and Europe as an entrepreneur, investor, board member and advisor. Her experience covers a variety of areas including software, e-commerce, digital health and clinical research. She recently served as an Entrepreneur-in-Residence at the Advanced Technology Development Center, the state incubator based at Georgia Institute of Technology. She is the Chief Growth Officer for Corps Team, a US-based search and staffing firm supporting startups to the Fortune 500. Jane also serves on the board of London Stock Exchange Main Market listed Edinburgh Worldwide Investment Trust plc, which invests globally in high growth companies; and Radyus Research, a US-based privately held company that advises on drug discovery, lead candidate selection, and enabling studies.
Iain Ross has over 40 years’ experience in the international life sciences and technology sectors and has held significant roles in multi-national pharmaceutical and biotech companies. He has completed multiple financing transactions and has over 30 years’ experience in cross-border management as a chairman or CEO. He has led or participated in eight IPOs and has direct experience of M&A transactions in Europe, the USA and the Pacific Rim. Currently he is Chairman of NASDAQ listed Silence Therapeutics plc, Executive Chairman of ReNeuron Group plc and internationally holds other non-executive director roles.
Further information on Jane McCracken and Iain Ross disclosed in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies is set out below.
Commenting, Ian Ritchie, Chairman of Tern, said: “I am delighted to welcome Jane and Iain to the Tern Board. I believe their skills and experience will be invaluable as we focus on generating returns for our shareholders from realisations. I would also like to take this opportunity to thank Sarah and Alan for their significant contributions to Tern and wish them well for the future.”
